Orally administered microencapsulated Bordetella pertussis fimbriae protect mice from B. pertussis respiratory infection.
Fimbriae from Bordetella pertussis have been encapsulated in poly(lactide-co-glycolide) microparticles of a size appropriate for uptake by the immune inductive tissues of the gastrointestinal tract. Mice were immunized by oral gavage with a single dose of 10 micrograms of microencapsulated fimbriae. The resulting immune responses were compared with those resulting from intraperitoneal injection of mice with equivalent amounts of fimbriae absorbed onto alhydrogel. The examination of serum and mucosal secretions, collected over a 6-week period, for specific antifimbrial antibodies clearly demonstrated that only orally immunized animals mounted measurable immune responses in external secretions. Six weeks after immunization, all immunized animals were protected against intranasal challenge with live B. pertussis.
Microbial Antigens Department, Centre for Applied Microbiology & Research, Porton Down, Salisbury, Wiltshire, United Kingdom.
D H
DH
Jones
B W
BW
McBride
C
C
Thornton
D T
DT
O'Hagan
A
A
Robinson
G H
GH
Farrar
D000284:Administration, Oral; D000818:Animals; D001886:Bordetella pertussis / Q000276:immunology*; D005260:Female; D010861:Fimbriae, Bacterial / Q000276:immunology*; D007114:Immunization; D007074:Immunoglobulin G / Q000032:analysis; D019344:Lactic Acid; D051379:Mice; D011100:Polyglycolic Acid; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011108:Polymers / Q000008:administration & dosage*; D011817:Rabbits; D014917:Whooping Cough / Q000517:prevention & control*
D007074:Immunoglobulin G; D011108:Polymers; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid